Metropolitan Life Insurance Company (MetLife)’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-2,495
| Closed | -$5.99K | – | 1216 |
|
|
2024
Q1 | $5.99K | Buy |
+2,495
| New | +$5.36K | ﹤0.01% | 2236 |
|
|
2023
Q4 | – | Sell |
-4,595
| Closed | -$5.01K | – | 2372 |
|
|
2023
Q3 | $5.01K | Hold |
4,595
| – | – | ﹤0.01% | 2391 |
|
|
2023
Q2 | $10.5K | Hold |
4,595
| – | – | ﹤0.01% | 2275 |
|
|
2023
Q1 | $11.2K | Sell |
4,595
-610
| -12% | -$1.4K | ﹤0.01% | 2114 |
|
|
2022
Q4 | $9.94K | Buy |
5,205
+111
| +2% | +$236 | ﹤0.01% | 2282 |
|
|
2022
Q3 | $12.2K | Buy |
+5,094
| New | +$14.1K | ﹤0.01% | 2244 |
|
|
2022
Q1 | – | Sell |
-20,131
| Closed | -$79.3K | – | 2501 |
|
|
2021
Q4 | $79.3K | Buy |
20,131
+760
| +4% | +$3.69K | ﹤0.01% | 2595 |
|
|
2021
Q3 | $93.2K | Buy |
+19,371
| New | +$79.5K | ﹤0.01% | 2563 |
|
|
2019
Q3 | – | Sell |
-15,381
| Closed | -$96.7K | – | 2601 |
|
|
2019
Q2 | $96.7K | Hold |
15,381
| – | – | ﹤0.01% | 2326 |
|
|
2019
Q1 | $85.5K | Buy |
15,381
+621
| +4% | +$3.77K | ﹤0.01% | 2400 |
|
|
2018
Q4 | $98K | Hold |
14,760
| – | – | ﹤0.01% | 2283 |
|
|
2018
Q3 | $157K | Hold |
14,760
| – | – | ﹤0.01% | 2172 |
|
|
2018
Q2 | $177K | Hold |
14,760
| – | – | ﹤0.01% | 2025 |
|
|
2018
Q1 | $126K | Hold |
14,760
| – | – | ﹤0.01% | 2172 |
|
|
2017
Q4 | $146K | Sell |
14,760
-18,442
| -56% | -$192K | ﹤0.01% | 2091 |
|
|
2017
Q3 | $408K | Hold |
33,202
| – | – | ﹤0.01% | 1821 |
|
|
2017
Q2 | $546K | Hold |
33,202
| – | – | ﹤0.01% | 1626 |
|
|
2017
Q1 | $476K | Sell |
33,202
-922
| -3% | -$13.7K | ﹤0.01% | 1680 |
|
|
2016
Q4 | $472K | Hold |
34,124
| – | – | ﹤0.01% | 1777 |
|
|
2016
Q3 | $617K | Hold |
34,124
| – | – | ﹤0.01% | 1572 |
|
|
2016
Q2 | $490K | Hold |
34,124
| – | – | ﹤0.01% | 1720 |
|
|
2016
Q1 | $408K | Hold |
34,124
| – | – | ﹤0.01% | 1713 |
|
|
2015
Q4 | $454K | Buy |
34,124
+6,666
| +24% | +$82K | ﹤0.01% | 1678 |
|
|
2015
Q3 | $295K | Buy |
27,458
+4,697
| +21% | +$51.3K | ﹤0.01% | 1994 |
|
|
2015
Q2 | $183K | Sell |
22,761
-4,405
| -16% | -$32.4K | ﹤0.01% | 2456 |
|
|
2015
Q1 | $180K | Buy |
27,166
+232
| +0.9% | +$1.58K | ﹤0.01% | 2108 |
|
|
2014
Q4 | $172K | Hold |
26,934
| – | – | ﹤0.01% | 2512 |
|
|
2014
Q3 | $266K | Buy |
26,934
+12,249
| +83% | +$131K | ﹤0.01% | 2175 |
|
|
2014
Q2 | $165K | Sell |
14,685
-11,457
| -44% | -$123K | ﹤0.01% | 2619 |
|
|
2014
Q1 | $317K | Sell |
26,142
-842
| -3% | -$10.8K | ﹤0.01% | 2126 |
|
|
2013
Q4 | $340K | Hold |
26,984
| – | – | ﹤0.01% | 2089 |
|
|
2013
Q3 | $448K | Buy |
26,984
+10,528
| +64% | +$177K | ﹤0.01% | 1821 |
|
|
2013
Q2 | $250K | Buy |
+16,456
| New | +$250K | ﹤0.01% | 2186 |
|
Other funds holding LXRX
AG
B
O
NMC
Metropolitan Life Insurance Company (MetLife)'s LXRX Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2024, closing a stake of 2,495 shares — an estimated $5.99K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in LXRX in Q2 2013 and held it in 33 quarters. The position peaked at $617K in Q3 2016. 127 funds tracked by Wall St. Rank hold LXRX as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Lexicon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 2,495 Lexicon Pharmaceuticals shares in Q2 2024, an estimated $5.99K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 33 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Lexicon Pharmaceuticals position peaked at $617K in Q3 2016.
- 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.